Christmas Sale Brilliant Violet 510™ Anti-human Cd197 (ccr7) Easy Returns [f0sPXmig]
CCR7, also known as CD197, is a chemokine receptor that binds CCL19 and CCL21. CCR7 and its ligands link innate and adaptive immunity by affecting interactions between T cells and dendritic cells and their downstream effect. Naïve T cells enter the l
Secure Shopping
100% Safe Guarantee
Free Shipping
On orders over $30
Money-Back
30-Day Guarantee
Christmas Sale Brilliant Violet 510™ Anti-human Cd197 (ccr7) Easy Returns [f0sPXmig]
CCR7, also known as CD197, is a chemokine receptor that binds CCL19 and CCL21. CCR7 and its ligands link innate and adaptive immunity by affecting interactions between T cells and dendritic cells and their downstream effect. Naïve T cells enter the lymph node through high endothelial venules, which express CCL21. Dendritic cells and macrophages enter the lymph node through afferent lymphatics. The encounter of T cells and dendritic cells in the T cell zone is CCR7-dependent. In addition, during immunological surveillance, B cells recirculate between B-cell-rich compartments (follicles or B cell zones) in secondary lymphoid organs, surveying for antigen. After antigen binding, B cells move to the boundary of B and T zones to interact with T-helper cells; this B cell migration is directed by CCR7 and its ligands. CCR7-positive cancer cell expression has been associated with lymph node metastasis.
PRODUCT DETAILS
Clone: G043H7
Antibody Type: Monoclonal
Reactivity: Human
Format: BV510
Host: Mouse
Isotype: IgG2a, κ
Applications: FC - Quality tested
Regulatory Status: RUO
Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.
What Our Customers Say
Absolutely no complaints!
Can't function without it now.
- Sawyer Q..
Absolutely no complaints!
Works great, and looks very stylish.
- Graham M..
Absolutely no complaints!
Simply awesome. I really love it.
- Tyson O..